When put together with our current findings, this suggests a feedback loop driving acquired resistance: fibroblast-poor CRCs, upon KRAS inhibition, recruit and activate fibroblasts into CAFs, which in turn support CRC growth independently of KRAS signaling. Here, KRAS is linked to colorectal carcinoma.